comprehensive -WSS

comprehensive

author：explore 2025-09-05 11:23:09 - browse：1285

Moderna chairman Noubar Afeyan exuded star power earlier this month as he commanded the spotlight at BIO 2023, the industry’s largest convention.

Basking in the accolades heaped on Moderna’s celebrated Covid-19 vaccine, Afeyan regaled the Boston audience with the company’s origin story and greeted fans who lined up to snap selfies with him. Stuart Cable, a partner in the law firm Goodwin who’s represented Moderna and joined Afeyan on stage, called Moderna “arguably the most successful story in the history of biotechnology.”

But the Cambridge, Mass.-based company can’t afford to rest on its laurels. Two and a half years after its vaccine liberated tens of millions from pandemic lockdowns — ringing up more than $36 billion in sales so far — Moderna faces a changing business and regulatory environment. Demand for Covid shots is waning, a backlash over drug prices is gaining traction, and questions about its next act loom.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The high cost of giving birth even with insurance
Next article： Canadians with cystic fibrosis outlive Americans by a decade

focus

WSS

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

A letter from the executive editor: The 2023 STATUS List

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

Helping hospitals and community health centers plan for resilience

Top Ukrainian generals say counteroffensive is 'going to plan' as losses mount

Venture capitalist Bob Kocher on the state of digital health

explore

comprehensive

focus

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Use doctors trained outside the U.S. to ease the physician shortage

Novavax promises a turnaround & Lilly roils the obesity market

It's time to retire 'poor historian' from clinicians' vocabularies

United colonoscopy coverage change 'may cost lives,' doctors say

'Screen and refer' systems are hurting patients

Walensky prepares to leave CDC — and Congress — behind

A letter from the executive editor: The 2023 STATUS List

Virginia high school admissions case could be legal follow

Solving academic medical centers' existential crisis

Wikipedia

Prescription digital therapeutics are key to pharma’s future

NVIDIA and Google execs on the future of AI and drug discovery

Addiction experts warn against a second 'war on drugs'

Dexcom's push to bring CGM to type 2 diabetes patients

Archived: an online chat discussing Ebola, vaccines, and a new epidemic

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

leisure time

focus

focus

Wikipedia